Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.

Journal article

OBJECT: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement. It has been postulated to improve outcomes in patients undergoing coronary artery bypass surgery and urgent reperfusion therapy for ST elevation myocardial infarction. We aimed at evaluating the risk/benefit profile of pexelizumab (bolus + infusion) versus placebo on top of current approaches in the management of patients with ST elevation myocardial infarction or undergoing coronary artery bypass. METHODS: We c...

Expand abstract

Authors: Testa, L; Van Gaal, W; Bhindi, R; Biondi-Zoccai, G; Abbate, A

• Journal: Journal of thoracic and cardiovascular surgery
• Volume: 136
• Issue: 4
• Pages: 884-893
• Publication date: 2008-10-01
• DOI: 10.1016/j.jtcvs.2007.12.062
• EISSN: 1097-685X
• ISSN: 0022-5223
• Language: English
• Keywords: Single-Chain Antibodies; Combined Modality Therapy; Dose-Response Relationship, Drug; Aged; Infusions, Intravenous; Drug Administration Schedule; Female; Coronary Artery Bypass; Survival Analysis; Coronary Angiography; Complement Inactivating Agents; Antibodies, Monoclonal; Randomized Controlled Trials as Topic; Middle Aged; Odds Ratio; Risk Assessment; Myocardial Ischemia; Treatment Outcome; Myocardial Infarction; Confidence Intervals; Severity of Illness Index; Male; Humans; Adult; Electrocardiography; Reference Values; Antibodies, Monoclonal, Humanized; Prognosis